PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PolyPid Ltd. reports FDA acceptance with Priority Review for its NDA submission of D-PLEX100 aimed at preventing surgical site infections in abdominal colorectal surgeries. The FDA PDUFA goal date is set for November 28, 2026, ahead of prior guidance, with a potential commercial launch in early 2027 under an exclusive U.S. and Canada partnership wi…